Open access

589 Efficacy of oncolytic vaccinia virus requires infection of suppressive immune cells in the tumor microenvironment leading to their reprogramming and deletion
Kristin DePeaux, Paolo Vignali, Saumendra Sarkar, Greg Delgoffe

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A352-A353; DOI: 10.1136/jitc-2020-SITC2020.0589
590 Pre-conditioning of the tumor microenvironment with oncolytic reovirus converts CD3-bispecific antibody treatment into effective immunotherapy
Christianne Groeneveldt, Priscilla Kinderman, Diana JM van den Wollenberg, Ruben L van den Oever, Jim Middelburg, Dana AM Mustafa, Rob Hoeben, Sjoerd van der Burg, Thorbald van Hall, Nadine Van Montfoort

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A353-A354; DOI: 10.1136/jitc-2020-SITC2020.0590
591 Comparison of two oHSV Vectors for the treatment of glioblastoma
Joseph Jackson, Bonnie Hall, Lisa Bailey, E Chiocca, Justus Cohen

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A354; DOI: 10.1136/jitc-2020-SITC2020.0591
592 Enhancing the therapeutic potential of oncolytic adenoviruses with vSENS™ technology
Goo-Young Kim, Ji Yeon Son, So Jin Lee, Sang Woo Jo, Changhoon In, Sang Hoon Kim, Joon Young Park, So-Young Kim, Gyu-Young Moon, Ji-Hye Choi, Suk-Hwan Kim, Minhyuk Yun, Hye Yeong Nam, Helen Cho

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A354-A355; DOI: 10.1136/jitc-2020-SITC2020.0592
593 Tumoral melanosis mimicking residual melanoma After T-VEC treatment
Song Park, Ata Moshiri, Rouba Hadi, Austin Green, Jennifer Gardner, Coley Doolittle-Amieva

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A355-A356; DOI: 10.1136/jitc-2020-SITC2020.0593
596 Armed myxoma virus demonstrates therapeutic activity in xenograft models
Lino Torres-Dominguez, Lina Franco, Mario Abrantes, Benjamin Walker, Zachary Tacner, Cassandra Kien, Natalie Elliott, Anna Waters, Grant McFadden, Steven Potts, Leslie Sharp

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A356-A357; DOI: 10.1136/jitc-2020-SITC2020.0596
594 BT-001, an oncolytic vaccinia virus armed with a Treg-depleting human recombinant anti-CTLA4 antibody and GM-CSF to target the tumor microenvironment
Monika Semmrich, Jean-Baptiste Marchand, Laetitia Fend, Matilda Rehn, Nathalie Silvestre, Linda Mårtensson, Johann Foloppe, Ingrid Teige, Eric Quéméneur, Björn Frendeus

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A356; DOI: 10.1136/jitc-2020-SITC2020.0594
598 Reversal of epigenetic silencing of cGAS and STING in melanoma enhances the activity of tumor infiltrating lymphocytes
Rana Falahat, James Mulé, Anders Berglund, Patricio Perez- Villarroel, Ryan Putney, Shari Pilon-Thomas, Glen Barber

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A357-A358; DOI: 10.1136/jitc-2020-SITC2020.0598
597 In situ vaccination with oncolytic vesicular stomatitis virus improves anti-tumor immune response and outcome in bladder cancer
Coby Rangsitratkul, Christine Lawson, Lee-Hwa Tai

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A357; DOI: 10.1136/jitc-2020-SITC2020.0597
599 New checkpoints controlling function of cytotoxic lymphocytes infiltrating human carcinoma
Anna Herbstritt, Elfriede Noessner, Petra Prinz, Mani Kadiyala, Melissa Maxwell, Dingxue Yan, James Cardia, Simon Fricker

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A358; DOI: 10.1136/jitc-2020-SITC2020.0599

Main menu

Open access

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

Open access

Pages